Vitamin D Supplementation May Offset Bone Loss Caused by canagliflozin

Written By :  Dr. Kamal Kant Kohli
Published On 2022-06-28 05:30 GMT   |   Update On 2022-06-28 08:10 GMT
Advertisement

SGLT2 inhibitors have been shown to slow the progression of diabetes-related kidney disease and is increasingly being considered as a first-line treatment option for people with diabetes who have a high risk for developing kidney and heart disease. However, some studies have found SGLT inhibitors to negatively affect bone health by accelerating loss of bone mineral density and hampering the activation of vitamin D by the body.

Advertisement

According to a new study, Vitamin D supplementation may help offset damaging bone loss that occurs in some people who take canagliflozin a commonly prescribed SGLT2 inhibitor for diabetes.

The Research will be presented at the American Physiological Society (APS) and American Society for Nephrology Control of Renal Function in Health and Disease conference in Charlottesville, Virginia.

The combination of these events can increase the risk of bone fracture. Researchers from the University of Maryland School of Medicine hypothesize that people who already have lower-than-normal levels of vitamin D have an even higher risk of bone loss and possible fracture when taking SGLT2 inhibitors.

The research team studied adults from an Old Order Amish community in Lancaster, Pennsylvania. The researchers explained that they chose this population due to the availability of extensive genetic sequencing data, but also because, unlike commercially processed milk, the farm-fresh milk many people in the Amish community drink is not fortified with vitamin D. Therefore, it is more likely that Amish people consume less vitamin D from their diet than the general population in the U.S.

The volunteers-some of whom were found to have preexisting low vitamin D levels-took canagliflozin, an SGLT2 inhibitor, for five days before and after they were given vitamin D supplements. The researchers found that in people who were vitamin D-deficient, canagliflozin led to a significant decrease (31%) in the levels of a metabolite used to measure vitamin D levels, but a much smaller decrease (7%) in those with normal vitamin D status. The supplements then boosted levels of parathyroid hormone, which regulates calcium levels in the blood and vitamin D levels in the bones.

The research team explained that short-term study of vitamin D supplements to counter the adverse effects of SGLT2 inhibitors on bone health shows promising results, but more research is needed. "Longer term follow-up will be required to determine whether this accelerated loss of bone mineral density will eventually translate into an increased risk of bone fracture over the course of 10–20 years of chronic therapy," said Zhinous Yazdi, MD, first author of the study. "Accordingly, we recommend that patients and physicians consider the possibility of taking vitamin D supplements to restore normal vitamin D status in vitamin D-deficient patients receiving (or who will receive) SGLT2 inhibitors."

Reference:

Control of Renal Function in Health and Disease Conference June 26–30, 2022 Charlottesville, Virginia #KidneyCamp

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News